Stifel Upgrades Black Diamond Therapeutic to Buy, Raises Price Target to $10
Portfolio Pulse from richadhand@benzinga.com
Stifel analyst Bradley Canino has upgraded Black Diamond Therapeutic (NASDAQ:BDTX) from Hold to Buy and raised the price target from $2 to $10.
June 30, 2023 | 8:45 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Black Diamond Therapeutic's stock has been upgraded to Buy by Stifel with a raised price target of $10.
The upgrade from Hold to Buy by Stifel indicates a positive outlook for Black Diamond Therapeutic. The significant increase in the price target from $2 to $10 suggests that the analyst sees substantial upside potential for the stock. This could lead to increased investor interest and upward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100